Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $144

Benzinga Newsdesk www.benzinga.com Negative 94.6%

Neg 94.6% Neu 0% Pos 0%

Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $150 to $144.